Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective cohort study of Dolutegravir and Lamivudine assessing efficacy and safety in HIV-infected HAART-treated Patients : DOLULAM Pilot Study

Next Previous
Trial Profile

A prospective cohort study of Dolutegravir and Lamivudine assessing efficacy and safety in HIV-infected HAART-treated Patients : DOLULAM Pilot Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms DOLULAM

    • Most Recent Events

    • 01 Oct 2017 Results of virological substudy assessing the prevalence of M184I/V mutations at dual therapy initiation using historical DNA/RNA genotypes and baseline DNA genotype obtained by next-generation sequencing (NGS) published in the Journal of Antimicrobial Chemotherapy
    • 26 Jul 2017 96 weeks results from maintenance DOLULAM study presented at the 9th International AIDS Society Conference on HIV Science
    • 26 Jul 2017 Results of a substudy assessing the prevalence of M184I/V mutations at time of dual-therapy initiation presented at the 9th International AIDS Society Conference on HIV Science
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top